José L. Cohen
French Institute of Health and Medical Research
ImmunologyGraft-versus-host diseaseMedicineIL-2 receptorBiology
What is this?
Publications 79
#1Caroline Pilon (French Institute of Health and Medical Research)H-Index: 6
#1C. PilonH-Index: 4
Last. Marie MatignonH-Index: 20
view all 8 authors...
High dose intravenous immunoglobulin (IVIG) are widely used after kidney transplantation and its biological effect on T and B cell phenotype in the context of maintenance immunosuppression was not documented yet. We designed a monocentric prospective cohort study of kidney allograft recipients with anti-HLA donor specific antibodies (DSA) without acute rejection on screening biopsies treated with prophylactic high-dose IVIG (2 g/kg) monthly for two months. Any previous treatment with Rituximab w...
#1Caroline Pilon (French Institute of Health and Medical Research)H-Index: 6
#1C. PilonH-Index: 4
Last. José L. Cohen (University of Paris-Est)
view all 13 authors...
The induction of a specific and sustainable tolerance is a major issue in organ transplantation. The discovery of the immunosuppressive properties of apoptotic cells in animal models has paved the way for their use in human transplantation. In this work, we aimed to define a stable, reproducible and clinically compatible production procedure of human apoptotic cells (Apo-cells). Using a clinically approved extracorporeal photopheresis technique, we have produced and characterized phenotypically ...
#1Claire LeiblerH-Index: 6
#2Anissa MoktefiH-Index: 5
Last. Vincent AudardH-Index: 26
view all 9 authors...
Fibrillary glomerulonephritis (FGN) is a rare glomerular disease characterized by glomerular deposition of randomly arranged non-amyloid fibrils. FGN has a poor renal prognosis and its optimal treatment is a medical challenge. Rituximab therapy has recently emerged as a promising approach even though its mechanism of action remains hypothetical. We describe the case of a 55-year-old woman with FGN successfully treated by rituximab. During the 36-month follow-up, she had three relapses of FGN, oc...
#1Maryam Khosravi (Razi University)H-Index: 1
#2Ali Bidmeshkipour (Razi University)H-Index: 8
Last. Mohammad Hossein Karimi (Shiraz University of Medical Sciences)H-Index: 14
view all 7 authors...
Mesenchymal stem cells (MSCs) are known for their ability to induce the conversion of conventional T cells (Tconvs) into induced regulatory T cells (iTregs) in specific inflammatory contexts. Stable Foxp3 expression plays a major role in the phenotypic and functional stability of iTregs. However, how MSCs induce stable Foxp3 expression remains unknown. We first investigated the role of cell–cell contact and cytokine secretion by bone marrow-derived MSCs (BM-MSCs) on the induction, stability, and...
4 CitationsSource
#1Benoît L. Salomon (University of Paris)H-Index: 36
#2Mathieu Leclerc (University of Paris)H-Index: 5
Last. José L. Cohen (University of Paris)H-Index: 24
view all 6 authors...
Tumor necrosis factor α (TNF) is a potent pro-inflammatory cytokine that has deleterious effect in some autoimmune diseases, which led to the use of anti-TNF drugs in some of these diseases. However, some rare patients treated with these drugs paradoxically develop an aggravation of their disease or new onset autoimmunity, revealing an immunosuppressive facet of TNF. A possible mechanism of this observation is the direct and positive effect of TNF on regulatory T cells (Tregs) through its bindin...
11 CitationsSource
#1Sina Naserian (French Institute of Health and Medical Research)H-Index: 4
#2Mathieu Leclerc (French Institute of Health and Medical Research)H-Index: 5
Last. José L. Cohen (French Institute of Health and Medical Research)H-Index: 24
view all 9 authors...
Acute graft-versus-host disease (aGVHD) represents a challenging complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Despite the intensive pre-clinical research in the field of prevention and treatment of aGVHD, and the presence of a well-established clinical grading system to evaluate human aGVHD, such a valid tool is still lacking for the evaluation of murine aGVHD. Indeed, several scoring systems have been reported, but none of them has been properly evaluated a...
8 CitationsSource
#1Claire Leibler (French Institute of Health and Medical Research)H-Index: 6
#2Allan Thiolat (French Institute of Health and Medical Research)H-Index: 8
Last. Philippe Grimbert (French Institute of Health and Medical Research)H-Index: 29
view all 9 authors...
Generation of de novo donor-specific antibodies ( dn DSAs) after renal transplant is recognized as the leading cause of late transplant failure. Hence, the optimal immunosuppressive strategies to limit dn DSA development need to be defined. Recent clinical trials using the novel costimulatory blockade agent CTLA4-Ig (Belatacept) have shown that kidney transplant recipients (KTRs) treated with Belatacept have better graft survival and function and a lower proportion of dn DSAs than control-treate...
17 CitationsSource
#1José L. Cohen (University of Paris)H-Index: 24
#2Kathryn J. Wood (John Radcliffe Hospital)H-Index: 67
ABSTRACTThree recent publications identified the TNF/TNR2 pathway as a new target to reduce graft-versus-host-disease through regulatory T cells activation or to potentially switch on a strong anti-leukemic effect through regulatory T cells blockade in allogeneic hematopoietic stem cell transplantation. This identified the TNF/TNR2 pathway as a swith and as a new target for immune checkpoint therapy to modulate the immune regulation in this clinical setting.
4 CitationsSource
#1Sebastien MauryH-Index: 4
#2José L. CohenH-Index: 24
Last. Mathieu LeclercH-Index: 5
view all 5 authors...
#1Salim HamdaniH-Index: 1
#2Allan ThiolatH-Index: 8
Last. C. PilonH-Index: 4
view all 11 authors...
Delayed and short course of rapamycin prevents organ rejection after allogeneic liver transplantation in rats
4 CitationsSource